View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
October 6, 2020

Coronavirus company news summary – NDIVIA’s supercomputer will support AI-based Covid-19 research – Fred Hutchinson opens Covid-19 clinical research centre

By Allie Nawrat

6 October 2020 

Bharat Biotech has partnered with ViroVax to use the latter’s adjuvant to boost the immune response of its Covid-19 vaccine candidate Covaxin. Bharat Biotech will have access to ViroVax’s Alhydroxiquim-II adjuvant technology to support its Covid-19 vaccine candidate, which is currently in Phase II clinical trials.

NVIDIA is creating a supercomputer named Cambridge-1 to enable artificial intelligence (AI)-based research on Covid-19, as well as other healthcare areas. Claimed to be the UK’s most powerful supercomputer, Cambridge-1 will be initially leveraged by GlaxoSmithKline, AstraZeneca, Guy’s and St Thomas’ NHS Foundation Trust, King’s College London and Oxford Nanopore Technologies for pharmaceutical research.

Fred Hutchinson Cancer Research Center has opened the new Covid-19 Clinical Research Center to help assess new interventions for the prevention and treatment of the disease. The new centre will offer a collaborative space for scientists and clinicians to work on Phase I through III clinical trials in participants diagnosed with Covid-19, and other infectious diseases in the future.

Biotechnology startup HDT Bio has completed a $3m seed funding round led by Zoic Capital for the development of its Covid-19 vaccine candidate, HDT-301. In alliance with the US National Institutes of Health, the vaccine is scheduled to begin clinical trials in the fourth quarter of this year.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology